183 related articles for article (PubMed ID: 16352726)
1. Controlling ligand substitution reactions of organometallic complexes: tuning cancer cell cytotoxicity.
Wang F; Habtemariam A; van der Geer EP; Fernández R; Melchart M; Deeth RJ; Aird R; Guichard S; Fabbiani FP; Lozano-Casal P; Oswald ID; Jodrell DI; Parsons S; Sadler PJ
Proc Natl Acad Sci U S A; 2005 Dec; 102(51):18269-74. PubMed ID: 16352726
[TBL] [Abstract][Full Text] [Related]
2. Bipyrimidine ruthenium(II) arene complexes: structure, reactivity and cytotoxicity.
Betanzos-Lara S; Novakova O; Deeth RJ; Pizarro AM; Clarkson GJ; Liskova B; Brabec V; Sadler PJ; Habtemariam A
J Biol Inorg Chem; 2012 Oct; 17(7):1033-51. PubMed ID: 22791215
[TBL] [Abstract][Full Text] [Related]
3. The contrasting chemistry and cancer cell cytotoxicity of bipyridine and bipyridinediol ruthenium(II) arene complexes.
Bugarcic T; Habtemariam A; Stepankova J; Heringova P; Kasparkova J; Deeth RJ; Johnstone RD; Prescimone A; Parkin A; Parsons S; Brabec V; Sadler PJ
Inorg Chem; 2008 Dec; 47(24):11470-86. PubMed ID: 19007206
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, characterization, and reaction pathways for the formation of a GMP adduct of a cytotoxic thiocyanato ruthenium arene complex.
Wang F; Habtemariam A; van der Geer EP; Deeth RJ; Gould R; Parsons S; Sadler PJ
J Biol Inorg Chem; 2009 Sep; 14(7):1065-76. PubMed ID: 19499253
[TBL] [Abstract][Full Text] [Related]
5. Tuning the reactivity of osmium(II) and ruthenium(II) arene complexes under physiological conditions.
Peacock AF; Habtemariam A; Fernández R; Walland V; Fabbiani FP; Parsons S; Aird RE; Jodrell DI; Sadler PJ
J Am Chem Soc; 2006 Feb; 128(5):1739-48. PubMed ID: 16448150
[TBL] [Abstract][Full Text] [Related]
6. Highly selective binding of organometallic ruthenium ethylenediamine complexes to nucleic acids: novel recognition mechanisms.
Chen H; Parkinson JA; Morris RE; Sadler PJ
J Am Chem Soc; 2003 Jan; 125(1):173-86. PubMed ID: 12515520
[TBL] [Abstract][Full Text] [Related]
7. Tuning the hydrolytic aqueous chemistry of osmium arene complexes with N,O-chelating ligands to achieve cancer cell cytotoxicity.
Peacock AF; Parsons S; Sadler PJ
J Am Chem Soc; 2007 Mar; 129(11):3348-57. PubMed ID: 17319668
[TBL] [Abstract][Full Text] [Related]
8. Organometallic ruthenium(II) diamine anticancer complexes: arene-nucleobase stacking and stereospecific hydrogen-bonding in guanine adducts.
Chen H; Parkinson JA; Parsons S; Coxall RA; Gould RO; Sadler PJ
J Am Chem Soc; 2002 Mar; 124(12):3064-82. PubMed ID: 11902898
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of cancer cell growth by ruthenium(II) arene complexes.
Morris RE; Aird RE; Murdoch Pdel S; Chen H; Cummings J; Hughes ND; Parsons S; Parkin A; Boyd G; Jodrell DI; Sadler PJ
J Med Chem; 2001 Oct; 44(22):3616-21. PubMed ID: 11606126
[TBL] [Abstract][Full Text] [Related]
10. Phenylazo-pyridine and phenylazo-pyrazole chlorido ruthenium(II) arene complexes: arene loss, aquation, and cancer cell cytotoxicity.
Dougan SJ; Melchart M; Habtemariam A; Parsons S; Sadler PJ
Inorg Chem; 2006 Dec; 45(26):10882-94. PubMed ID: 17173447
[TBL] [Abstract][Full Text] [Related]
11. Chloro half-sandwich osmium(II) complexes: influence of chelated N,N-ligands on hydrolysis, guanine binding, and cytotoxicity.
Peacock AF; Habtemariam A; Moggach SA; Prescimone A; Parsons S; Sadler PJ
Inorg Chem; 2007 May; 46(10):4049-59. PubMed ID: 17441712
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity relationships for cytotoxic ruthenium(II) arene complexes containing N,N-, N,O-, and O,O-chelating ligands.
Habtemariam A; Melchart M; Fernandez R; Parsons S; Oswald ID; Parkin A; Fabbiani FP; Davidson JE; Dawson A; Aird RE; Jodrell DI; Sadler PJ
J Med Chem; 2006 Nov; 49(23):6858-68. PubMed ID: 17154516
[TBL] [Abstract][Full Text] [Related]
13. Derivation of structure-activity relationships from the anticancer properties of ruthenium(II) arene complexes with 2-aryldiazole ligands.
Martínez-Alonso M; Busto N; Jalón FA; Manzano BR; Leal JM; Rodríguez AM; García B; Espino G
Inorg Chem; 2014 Oct; 53(20):11274-88. PubMed ID: 25302401
[TBL] [Abstract][Full Text] [Related]
14. Organometallic osmium(II) arene anticancer complexes containing picolinate derivatives.
van Rijt SH; Peacock AF; Johnstone RD; Parsons S; Sadler PJ
Inorg Chem; 2009 Feb; 48(4):1753-62. PubMed ID: 19146436
[TBL] [Abstract][Full Text] [Related]
15. Effect of cysteine thiols on the catalytic and anticancer activity of Ru(II) sulfonyl-ethylenediamine complexes.
Chen F; Romero-Canelón I; Habtemariam A; Song JI; Banerjee S; Clarkson GJ; Song L; Prokes I; Sadler PJ
Dalton Trans; 2022 Mar; 51(11):4447-4457. PubMed ID: 35226015
[TBL] [Abstract][Full Text] [Related]
16. New water-soluble ruthenium(II) terpyridine complexes for anticancer activity: synthesis, characterization, activation kinetics, and interaction with guanine derivatives.
Rilak A; Bratsos I; Zangrando E; Kljun J; Turel I; Bugarčić ŽD; Alessio E
Inorg Chem; 2014 Jun; 53(12):6113-26. PubMed ID: 24884156
[TBL] [Abstract][Full Text] [Related]
17. Design of Ru-arene Complexes for Antitumor Drugs.
Su W; Li Y; Li P
Mini Rev Med Chem; 2018; 18(2):184-193. PubMed ID: 28494728
[TBL] [Abstract][Full Text] [Related]
18. The Application of Reversible Intramolecular Sulfonamide Ligation to Modulate Reactivity in Organometallic Ruthenium(II) Diamine Complexes.
Kemp SA; Prior TJ; Savoie H; Boyle RW; Murray BS
Molecules; 2020 Jan; 25(2):. PubMed ID: 31936104
[TBL] [Abstract][Full Text] [Related]
19. Structure-activity relationships for organometallic osmium arene phenylazopyridine complexes with potent anticancer activity.
Fu Y; Habtemariam A; Basri AM; Braddick D; Clarkson GJ; Sadler PJ
Dalton Trans; 2011 Oct; 40(40):10553-62. PubMed ID: 21860862
[TBL] [Abstract][Full Text] [Related]
20. Catalysis of regioselective reduction of NAD+ by ruthenium(II) arene complexes under biologically relevant conditions.
Yan YK; Melchart M; Habtemariam A; Peacock AF; Sadler PJ
J Biol Inorg Chem; 2006 Jun; 11(4):483-8. PubMed ID: 16604356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
